PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
N Engl J Med. Author manuscript; available in PMC 2014 February 17.
Published in final edited form as:
PMCID: PMC3926433
NIHMSID: NIHMS546713

Association of a HOXB13 Variant with Breast Cancer

Shaheen Alanee, M.D., M.P.H., Fergus Couch, Ph.D., and Kenneth Offit, M.D., M.P.H.corresponding author

TO THE EDITOR

The role of homeobox 13 (HOXB13) in hormone-resistant breast cancer has been elucidated only recently. A missense mutation (c.251G→A; p.G84E; rs138213197) in HOXB13 associated with prostate cancer has been reported.1 We compared the frequency of rs138213197 C-T heterozygotes in 1170 patients with familial breast cancer (including 293 patients of Ashkenazi Jewish ancestry) and wild-type BRCA1 and BRCA2 mutations, 1053 patients with sporadic breast cancer (who were not tested for BRCA1/2), 1052 patients with colon cancer, and 1650 healthy controls.

Most patients with breast cancer (70%) were white women with a mean age at diagnosis of 53 years. Germline DNA extracted from blood was available through protocols approved by the institutional review board at the Memorial Sloan-Kettering Cancer Center. Written informed consent was obtained from some patients; in others, this requirement was waived since the analyzed data had no personal identifiers. Genotyping was performed with the use of the TaqMan allelic discrimination assay (Applied Biosystems). We verified the presence of the variant among suspected carriers with the use of Sanger sequencing.

Among 877 patients, 6 women with BRCA1/2 wild-type, familial breast cancer who were not of Ashkenazi Jewish ancestry were carriers of the rs138213197 variant (0.7%); this rate was seven times as high as the prevalence of the mutation among controls (0.1%) (odds ratio, 5.7; 95% confidence interval, 1.0 to 40.7; exact P = 0.02). The mutation carriers were mainly white women who were 38 to 77 years of age at diagnosis, and 4 patients had estrogen-receptor (ER)–positive tumors (Table 1).

Table 1
Patient and Tumor Characteristics of Six Heterozygous Carriers of HOXB13 Mutation (rs138213197) among BRCA-Negative Patients with Non-Ashkenazi Familial Breast Cancer.*

We observed 3 heterozygous carriers among the patients with sporadic breast cancer (0.3%), 1 heterozygous carrier among the patients with colon cancer, and no carriers of the mutation in the 293 patients with breast cancer who were of Ashkenazi Jewish ancestry. These findings show an association of this HOXB13 variant and a risk of BRCA1/2 wild-type, familial breast cancer. HOXB13 expression is increased in breast-cancer cells as compared with normal breast epithelium,2 and a high ratio of HOXB13 to interleukin-17B receptor (IL17BR) is suggested to signal impaired ER signaling and thus predict resistance to tamoxifen.3,4 As evidence of population heterogeneity, the mutation was not seen in Ashkenazi Jews but was observed in 1 patient with breast cancer who was of black and Native American race. These findings also show a moderate effect size (a risk that was approximately six times as high as the risk among persons without this mutation) for this HOXB13 variant, which is greater than the risk associated with cell-cycle–check-point kinase (CHEK2) mutations or common variants from genomewide association studies (approximately 1.1 to 2.5 times as high as the risk among persons without these genetic changes), but less than the risk of early-onset breast cancer associated with BRCA1/2 mutations (approximately 10 to 50 times as high as the risk among persons without these mutations). More data are needed to understand the pathogenic role of homeobox genes in breast-cancer susceptibility and the possible clinical usefulness of this HOXB13 variant.

Acknowledgments

Supported by the Breast Cancer Research Foundation, Niehaus Clinical Cancer Genetics Initiative, Sabin Family Fund, Sidney Kimmel Center for Prostate and Urologic Cancers, and a grant (CA128978) from the National Institutes of Health.

Footnotes

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

Contributor Information

Shaheen Alanee, Memorial Sloan-Kettering Cancer Center, New York, NY.

Fergus Couch, Mayo Clinic, Rochester, MN.

Kenneth Offit, Memorial Sloan-Kettering Cancer Center, New York, NY.

References

1. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–9. [PMC free article] [PubMed]
2. Cantile M, Pettinato G, Procino A, Feliciello I, Cindolo L, Cillo C. In vivo expression of the whole HOX gene network in human breast cancer. Eur J Cancer. 2003;39:257–64. [PubMed]
3. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607–16. [PubMed]
4. Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjold B, Stal O. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res. 2010;12:R53. [PMC free article] [PubMed]